Statyny a ryzyko cukrzycy – czy rzeczywiście problem kliniczny? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2013
Słowa kluczowe:
statyny, cukrzyca, ryzyko, prewencja
##plugins.themes.bootstrap3.article.main##
Abstrakt
Statyny są lekami powszechnie stosowanymi w prewencji chorób sercowo-naczyniowych. Pomimo dobrej tolerancji statyny nie są pozbawione działań niepożądanych. Jednym z ostatnio podnoszonych problemów jest ryzyko zwiększenia częstości pojawienia się cukrzycy w trakcie ich stosowania. Badania eksperymentalne wskazały potencjalne mechanizmy sprzyjające zwiększeniu glikemii. Analiza przeprowadzonych badań klinicznych wskazuje, że działanie to nie jest jednakowe dla wszystkich statyn. W zależności od doboru badań wyznaczone ryzyko względne zachorowania na cukrzycę w trakcie leczenia statyną waha się od 1,03 aż do 1,48. W artykule dokonano przeglądu dostępnego piśmiennictwa na ten temat.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pikto-Pietkiewicz , W., & Rawdanowicz , J. (2013). Statyny a ryzyko cukrzycy – czy rzeczywiście problem kliniczny? . Kardiologia W Praktyce, 7(1), 4-12. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1572
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Endo A., Kuroda M., Tsujita Y.: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo) 1977; 29(12): 1346-1348.
2. Schachter M.: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 2005; 19: 117-125.
3. Cybulska B., Kłosiewicz-Latoszek L.: Leki hipolipemizujące. W: Kardiologia. Podręcznik oparty na zasadach EBM. Tom 2. Szczeklik A., Tendera M. (red.). Medycyna Praktyczna, Kraków 2010: 1167-1168.
4. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S.: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103(15): 1933-1935.
5. Park K.W., Hwang K.K., Cho H.J., Hur J., Yang H.M., Yoon C.H., Kang H.J., Oh B.H., Park Y.B., Kim H.S.: Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells inhypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin. Chim. Acta 2007; 388(1-2): 156-166.
6. Bruegel M., Teupser D., Haffner I., Mueller M., Thiery J.: Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin. Exp. Pharmacol. Physiol. 2006; 33(12): 1144-1149.
7. Zeichner S., Mihos C.G., Santana O.: The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J. Cancer Res. Ther. 2012; 8(2): 176-183.
8. Dunne J.A., Bailey M.A., Griffin K.J., Sohrabi S., Coughlin P.A., Scott D.J.: Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A Systematic Review of the Literature. Curr. Vasc. Pharmacol. 2012 [online].
9. Sadowitz B., Maier K.G., Gahtan V.: Basic science review: statin therapy – Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc. Endovascular Surg. 2010; 44: 241-251.
10. Yada T., Nakata M., Shiraishi T. et al.: Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br. J. Pharmacol. 1999; 126: 1205-1213.
11. Ishikawa M., Okajima F., Inoue N. et al.: Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J. Atheroscler. Thromb. 2006; 13: 329-335.
12. Sampson U.K., Linton M.F., Fazio S.: Are statins diabetogenic? Curr. Opin. Cardiol. 2011; 26(4): 342-7.
13. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A.: Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325-331.
14. Kruit J.K., Kremer P.H., Dai L. et al.: Cholesterol efflux via ATP-binding cassette transporter A1(ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Experimental evidence that cellular cholesterol fluxes regulate insulin export by the β-cell. Diabetologia 2010; 53: 1110-1119.
15. Nakata M., Uto N., Maruyama I., Yada T.: Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6. Cell Struct. Funct. 1999; 24: 451-455.
16. Chamberlain L.H.: Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001; 507: 357-361.
17. Goldstein M.R., Mascitelli L.: Statin-induced diabetes: perhaps, it’s the tip of the iceberg. QJM 2011; 104(2): 174-178.
18. Goldfine A.B.: Statins: Is It Really Time to Reassess Benefits and Risks? N. Engl. J. Med. 2012; 366: 1752-1755.
19. Colbert J.D., Stone J.A.: Statin use and the risk of incident diabetes mellitus: a review of the literature. Can. J. Cardiol. 2012; 28(5): 581-589.
20. Sattar N., Preiss D., Murray H.M.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 2010; 375(9716): 735-742.
21. Scandinavian Simvastatin Survival Study group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
22. de Lemos J.A., Blazing M.A., Wiviott S.D. et al.; A to Z Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292(11): 1307-1316.
23. Downs J.R., Clearfield M., Weis S. et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
24. Barzilay J.I., Davis B.R., Pressel S.L. et al.; ALLHAT Collaborative Research Group: Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ. Cardiovasc. Qual. Outcomes 2012; 5: 153-162.
25. Sever P.S., Dahlof B., Poulter N.R. et al.; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158.
26. Kjekshus J., Apetrei E., Barrios V. et al.: Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007; 357: 2248-2261.
27. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico): Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital. Heart J. 2000; 1: 810-820.
28. Collins R., Armitage J., Parish S., Sleigh P., Peto R.; for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
29. Pedersen T.R., Faergeman O., Kastelein J.J. et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: Highdose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294(19): 2437-2445.
30. Ridker P.M., Danielson E., Fonseca F.A.H. et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
31. Keech A., Colquhoun D., Best J. et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose-results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
32. Nakamura H., Arakawa K., Itakura H. et al.: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
33. Shepherd J., Blauw G.J., Murphy M.B. et al.; PROSPER Study Group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
34. Cannon C.P., Braunwald E., McCabe C.H. et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350(15): 1495-1504.
35. Armitage J., Bowman L., Wallendszus K. et al.; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376(9753): 1658-1669.
36. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006; 355: 549-559.
37. Zaharan N.L., Williams D., Bennett K.: Statins and Risk of Treated Incident Diabetes in a Primary Care Population. Br. J. Clin. Pharmacol. 2012 Jul 30 [online: doi: 10.1111/j.1365-2125.2012.04403.x].
38. LaRosa J.C., Grundy S.M., Waters D.D. et al.; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005; 352(14): 1425-1435.
39. Culver A.L., Ockene I.S., Balasubramanian R., Olendzki B.C., Sepavich D.M., Wactawski-Wende J., Manson J.E., Qiao Y., Liu S., Merriam P.A., Rahilly-Tierny C., Thomas F., Berger J.S., Ockene J.K., Curb J.D., Ma Y.: Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch. Intern. Med. 2012; 172(2): 144-152.
40. Freeman D., Norrie J., Sattar N. et al.: Pravastatin and the development of diabetes: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
41. Abbas A., Milles J., Ramachandran S.: Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia. Clin. Med. Insights Endocrinol. Diabetes 2012; 5: 13-30.
42. Amarenco P., Goldstein L.B., Szarek M., Sillesen H., Rudolph A.E., Callahan A. 3rd, Hennerici M., Simunovic L., Zivin J.A., Welch K.M.; SPARCL Investigators: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38(12): 3198-3204.
43. Shaw J.E., Sicree R.A., Zimmet P.Z.: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010; 87: 4-14.
44. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J.: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380(9841): 565-571.
45. Ridker P.M., Danielson E., Fonseca F.A. et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
46. Xu Y., Zhao Z., Li X., Bi Y., Xu M., Ning G.: Relationships between C-reactive protein, white blood cell count, and insulin resistance in a Chinese population. Endocrine 2011; 39(2): 175-181.
47. Weng C.M., Chou C.H., Huang Y.Y., Lin C.C., Liu Y.W., Tsai W.C.: Increased C-reactive protein is associated with future development of diabetes mellitus in essential hypertensive patients. Heart Vessels 2010; 25(5): 386-391.
48. Belfki H., Ben Ali S., Bougatef S., Ben Ahmed D., Haddad N., Jmal A., Abdennebi M., Ben Romdhane H.: Association between C-reactive protein and type 2 diabetes in a Tunisian population. Inflammation 2012; 35(2): 684-689.
49. Wannamethee S.G., Shaper A.G., Lennon L., Morris R.W.: Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke and type 2 diabetes mellitus. Arch. Intern. Med. 2005; 165: 2644-2650.
50. Hanley A.J.G., Karter A.J., Williams K. et al.: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome. The insulin resistance atherosclerosis study. Circulation 2005; 112: 3713-3721.
51. Wilson P.F., D’Agostino R.B., Parise H., Sullivan L., Meigs J.B.: Metabolic syndrome as a predictor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
52. Liu S., Tinker L., Song Y., Rifai N., Bonds D.E., Cook N.R., Heiss G., Howard B.V., Hotamisligil G.S., Hu F.B., Kuller L.H., Manson J.E.: A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch. Intern. Med. 2007; 167(15): 1676-1685.
53. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327-334.
54. Thorand B., Löwel H., Schneider A., Kolb H., Meisinger C., Fröhlich M., Koenig W.: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch. Intern. Med. 2003; 163(1): 93-99.
55. Montonen J., Drogan D., Joost H.G., Boeing H., Fritsche A., Schleicher E., Schulze M.B., Pischon T.: Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur. J. Epidemiol. 2011; 26(1): 29-38.
56. Samaropoulos X.F., Light L., Ambrosius W.T., Marcovina S.M., Probstfield J., Jr D.C.: The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res. Clin. Pract. 2012; 95(3): 389-398.
57. Simsek S., Schalkwijk C.G., Wolffenbuttel B.H.: Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes – the CORALL study. Diabet. Med. 2012; 29(5): 628-631.
58. Ma T., Chang M.H., Tien L., Liou Y.S., Jong G.P.: The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging 2012; 29(1): 45-51.
59. Ose L., Budinski D., Hounslow N., Arneson V.: Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010; 210(1): 202-208.
60. Teramoto T.: Pitavastatin: clinical effects from the LIVES Study. Atheroscler. Suppl. 2011; 12(3): 285-288.
61. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Shin E.K.: Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 2010; 55(12): 1209-1216.
62. Waters D.D., Ho J.E., DeMicco D.A., Breazna A., Arsenault B.J., Wun C.C., Kastelein J.J., Colhoun H., Barter P.: Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 2011; 57(14): 1535-1545.
63. Koh K., Quon M., Han S. et al.: Simvastatin improves flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776-782.
64. Coleman C., Reinhart K., Kluger K., White C.M.: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 2008; 24: 1359-1362.
65. Culver A., Ockene I., Balasubramanian R.: Statin use and risk of diabetes mellitus in postmenopausal women in the women’s health initiative. Arch. Intern. Med. 2012; 172: 144-152.
66. Mills E., Wu P., Chong G. et al.: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. Q. J. Med. 2011; 104: 109-124.
67. Preiss D., Seshasai S., Welsh P. et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-2564.
68. Rajpathak S., Kumbhani D., Crandall J. et al.: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-1929.
69. Sattar N., Preiss D., Murray H. et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
70. Wild S.H., Byrne Ch.D.: Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus. Evid. Based. Med. 2012; 17: 192-193.
71. Mancini G.B., Schulzer M.: Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation 1999; 99: 377-383.
72. Schulzer M., Mancini G.B.: ‘Unqualified success’ and ‘unmitigated failure’: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int. J. Epidemiol. 1996; 25: 704-712.
73. Tonelli M., Lloyd A., Clement F., Conly J., Husereau D., Hemmelgarn B., Klarenbach S., McAlister F.A., Wiebe N., Manns B.; Alberta Kidney Disease Network: Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011; 183(16): E1189-1202.
74. Rocco M.B.: Statins and diabetes risk: Fact, fiction, and clinical implications. Cleve. Clin. J. Med. 2012; 79(12): 883-893.
75. Danaei G., Finucane M.M., Lu Y. et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
76. Wang K.L., Liu C.J., Chao T.F., Huang C.M., Wu C.H., Chen S.J., Chen T.J., Lin S.J., Chiang C.E.: Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 2012; 60(14): 1231-1238.
77. Cannon C.P.: Balancing the benefits of statins versus a new risk – diabetes. The Lancet 2010; 375(9716): 700-701.
2. Schachter M.: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 2005; 19: 117-125.
3. Cybulska B., Kłosiewicz-Latoszek L.: Leki hipolipemizujące. W: Kardiologia. Podręcznik oparty na zasadach EBM. Tom 2. Szczeklik A., Tendera M. (red.). Medycyna Praktyczna, Kraków 2010: 1167-1168.
4. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S.: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103(15): 1933-1935.
5. Park K.W., Hwang K.K., Cho H.J., Hur J., Yang H.M., Yoon C.H., Kang H.J., Oh B.H., Park Y.B., Kim H.S.: Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells inhypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin. Chim. Acta 2007; 388(1-2): 156-166.
6. Bruegel M., Teupser D., Haffner I., Mueller M., Thiery J.: Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin. Exp. Pharmacol. Physiol. 2006; 33(12): 1144-1149.
7. Zeichner S., Mihos C.G., Santana O.: The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J. Cancer Res. Ther. 2012; 8(2): 176-183.
8. Dunne J.A., Bailey M.A., Griffin K.J., Sohrabi S., Coughlin P.A., Scott D.J.: Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A Systematic Review of the Literature. Curr. Vasc. Pharmacol. 2012 [online].
9. Sadowitz B., Maier K.G., Gahtan V.: Basic science review: statin therapy – Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc. Endovascular Surg. 2010; 44: 241-251.
10. Yada T., Nakata M., Shiraishi T. et al.: Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br. J. Pharmacol. 1999; 126: 1205-1213.
11. Ishikawa M., Okajima F., Inoue N. et al.: Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J. Atheroscler. Thromb. 2006; 13: 329-335.
12. Sampson U.K., Linton M.F., Fazio S.: Are statins diabetogenic? Curr. Opin. Cardiol. 2011; 26(4): 342-7.
13. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A.: Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325-331.
14. Kruit J.K., Kremer P.H., Dai L. et al.: Cholesterol efflux via ATP-binding cassette transporter A1(ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Experimental evidence that cellular cholesterol fluxes regulate insulin export by the β-cell. Diabetologia 2010; 53: 1110-1119.
15. Nakata M., Uto N., Maruyama I., Yada T.: Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6. Cell Struct. Funct. 1999; 24: 451-455.
16. Chamberlain L.H.: Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001; 507: 357-361.
17. Goldstein M.R., Mascitelli L.: Statin-induced diabetes: perhaps, it’s the tip of the iceberg. QJM 2011; 104(2): 174-178.
18. Goldfine A.B.: Statins: Is It Really Time to Reassess Benefits and Risks? N. Engl. J. Med. 2012; 366: 1752-1755.
19. Colbert J.D., Stone J.A.: Statin use and the risk of incident diabetes mellitus: a review of the literature. Can. J. Cardiol. 2012; 28(5): 581-589.
20. Sattar N., Preiss D., Murray H.M.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 2010; 375(9716): 735-742.
21. Scandinavian Simvastatin Survival Study group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
22. de Lemos J.A., Blazing M.A., Wiviott S.D. et al.; A to Z Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292(11): 1307-1316.
23. Downs J.R., Clearfield M., Weis S. et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
24. Barzilay J.I., Davis B.R., Pressel S.L. et al.; ALLHAT Collaborative Research Group: Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ. Cardiovasc. Qual. Outcomes 2012; 5: 153-162.
25. Sever P.S., Dahlof B., Poulter N.R. et al.; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158.
26. Kjekshus J., Apetrei E., Barrios V. et al.: Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007; 357: 2248-2261.
27. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico): Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital. Heart J. 2000; 1: 810-820.
28. Collins R., Armitage J., Parish S., Sleigh P., Peto R.; for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
29. Pedersen T.R., Faergeman O., Kastelein J.J. et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: Highdose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294(19): 2437-2445.
30. Ridker P.M., Danielson E., Fonseca F.A.H. et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
31. Keech A., Colquhoun D., Best J. et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose-results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
32. Nakamura H., Arakawa K., Itakura H. et al.: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
33. Shepherd J., Blauw G.J., Murphy M.B. et al.; PROSPER Study Group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
34. Cannon C.P., Braunwald E., McCabe C.H. et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350(15): 1495-1504.
35. Armitage J., Bowman L., Wallendszus K. et al.; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376(9753): 1658-1669.
36. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006; 355: 549-559.
37. Zaharan N.L., Williams D., Bennett K.: Statins and Risk of Treated Incident Diabetes in a Primary Care Population. Br. J. Clin. Pharmacol. 2012 Jul 30 [online: doi: 10.1111/j.1365-2125.2012.04403.x].
38. LaRosa J.C., Grundy S.M., Waters D.D. et al.; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005; 352(14): 1425-1435.
39. Culver A.L., Ockene I.S., Balasubramanian R., Olendzki B.C., Sepavich D.M., Wactawski-Wende J., Manson J.E., Qiao Y., Liu S., Merriam P.A., Rahilly-Tierny C., Thomas F., Berger J.S., Ockene J.K., Curb J.D., Ma Y.: Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch. Intern. Med. 2012; 172(2): 144-152.
40. Freeman D., Norrie J., Sattar N. et al.: Pravastatin and the development of diabetes: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
41. Abbas A., Milles J., Ramachandran S.: Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia. Clin. Med. Insights Endocrinol. Diabetes 2012; 5: 13-30.
42. Amarenco P., Goldstein L.B., Szarek M., Sillesen H., Rudolph A.E., Callahan A. 3rd, Hennerici M., Simunovic L., Zivin J.A., Welch K.M.; SPARCL Investigators: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38(12): 3198-3204.
43. Shaw J.E., Sicree R.A., Zimmet P.Z.: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010; 87: 4-14.
44. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J.: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380(9841): 565-571.
45. Ridker P.M., Danielson E., Fonseca F.A. et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
46. Xu Y., Zhao Z., Li X., Bi Y., Xu M., Ning G.: Relationships between C-reactive protein, white blood cell count, and insulin resistance in a Chinese population. Endocrine 2011; 39(2): 175-181.
47. Weng C.M., Chou C.H., Huang Y.Y., Lin C.C., Liu Y.W., Tsai W.C.: Increased C-reactive protein is associated with future development of diabetes mellitus in essential hypertensive patients. Heart Vessels 2010; 25(5): 386-391.
48. Belfki H., Ben Ali S., Bougatef S., Ben Ahmed D., Haddad N., Jmal A., Abdennebi M., Ben Romdhane H.: Association between C-reactive protein and type 2 diabetes in a Tunisian population. Inflammation 2012; 35(2): 684-689.
49. Wannamethee S.G., Shaper A.G., Lennon L., Morris R.W.: Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke and type 2 diabetes mellitus. Arch. Intern. Med. 2005; 165: 2644-2650.
50. Hanley A.J.G., Karter A.J., Williams K. et al.: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome. The insulin resistance atherosclerosis study. Circulation 2005; 112: 3713-3721.
51. Wilson P.F., D’Agostino R.B., Parise H., Sullivan L., Meigs J.B.: Metabolic syndrome as a predictor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
52. Liu S., Tinker L., Song Y., Rifai N., Bonds D.E., Cook N.R., Heiss G., Howard B.V., Hotamisligil G.S., Hu F.B., Kuller L.H., Manson J.E.: A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch. Intern. Med. 2007; 167(15): 1676-1685.
53. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327-334.
54. Thorand B., Löwel H., Schneider A., Kolb H., Meisinger C., Fröhlich M., Koenig W.: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch. Intern. Med. 2003; 163(1): 93-99.
55. Montonen J., Drogan D., Joost H.G., Boeing H., Fritsche A., Schleicher E., Schulze M.B., Pischon T.: Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur. J. Epidemiol. 2011; 26(1): 29-38.
56. Samaropoulos X.F., Light L., Ambrosius W.T., Marcovina S.M., Probstfield J., Jr D.C.: The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res. Clin. Pract. 2012; 95(3): 389-398.
57. Simsek S., Schalkwijk C.G., Wolffenbuttel B.H.: Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes – the CORALL study. Diabet. Med. 2012; 29(5): 628-631.
58. Ma T., Chang M.H., Tien L., Liou Y.S., Jong G.P.: The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging 2012; 29(1): 45-51.
59. Ose L., Budinski D., Hounslow N., Arneson V.: Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010; 210(1): 202-208.
60. Teramoto T.: Pitavastatin: clinical effects from the LIVES Study. Atheroscler. Suppl. 2011; 12(3): 285-288.
61. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Shin E.K.: Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 2010; 55(12): 1209-1216.
62. Waters D.D., Ho J.E., DeMicco D.A., Breazna A., Arsenault B.J., Wun C.C., Kastelein J.J., Colhoun H., Barter P.: Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 2011; 57(14): 1535-1545.
63. Koh K., Quon M., Han S. et al.: Simvastatin improves flow mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776-782.
64. Coleman C., Reinhart K., Kluger K., White C.M.: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 2008; 24: 1359-1362.
65. Culver A., Ockene I., Balasubramanian R.: Statin use and risk of diabetes mellitus in postmenopausal women in the women’s health initiative. Arch. Intern. Med. 2012; 172: 144-152.
66. Mills E., Wu P., Chong G. et al.: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. Q. J. Med. 2011; 104: 109-124.
67. Preiss D., Seshasai S., Welsh P. et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-2564.
68. Rajpathak S., Kumbhani D., Crandall J. et al.: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-1929.
69. Sattar N., Preiss D., Murray H. et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
70. Wild S.H., Byrne Ch.D.: Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus. Evid. Based. Med. 2012; 17: 192-193.
71. Mancini G.B., Schulzer M.: Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation 1999; 99: 377-383.
72. Schulzer M., Mancini G.B.: ‘Unqualified success’ and ‘unmitigated failure’: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int. J. Epidemiol. 1996; 25: 704-712.
73. Tonelli M., Lloyd A., Clement F., Conly J., Husereau D., Hemmelgarn B., Klarenbach S., McAlister F.A., Wiebe N., Manns B.; Alberta Kidney Disease Network: Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011; 183(16): E1189-1202.
74. Rocco M.B.: Statins and diabetes risk: Fact, fiction, and clinical implications. Cleve. Clin. J. Med. 2012; 79(12): 883-893.
75. Danaei G., Finucane M.M., Lu Y. et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
76. Wang K.L., Liu C.J., Chao T.F., Huang C.M., Wu C.H., Chen S.J., Chen T.J., Lin S.J., Chiang C.E.: Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 2012; 60(14): 1231-1238.
77. Cannon C.P.: Balancing the benefits of statins versus a new risk – diabetes. The Lancet 2010; 375(9716): 700-701.